Immunai utilizes multi-omic single-cell analysis and machine learning to enhance drug development by optimizing clinical trials and evaluating preclinical assets. The company addresses the challenge of identifying effective treatment regimens and critical targets in human diseases, facilitating the advancement of immunomodulatory therapies.
Funding
$295M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Drug development faces challenges in identifying effective treatment regimens and critical targets in human diseases. Optimizing clinical trials and evaluating preclinical assets remains difficult, hindering the advancement of immunomodulatory therapies.
Solution
Immunai leverages multi-omic single-cell analysis, machine learning, and functional genomics to address core challenges in drug development. The company's platform helps optimize clinical trials by identifying the right treatment regimens for specific patient populations. It also de-risks the translation of preclinical assets and facilitates target discovery and evaluation by pinpointing critical nodes in human disease. By combining an engineering-first approach with a deep understanding of the immune system, Immunai aims to accelerate the development of breakthrough medicines.
Target Audience
The primary customers are pharmaceutical companies, research institutions, and drug developers involved in the discovery and development of immunomodulatory drugs.
Features
- Multi-omic single-cell analysis to deeply profile immune cells
- Machine learning algorithms to identify patterns and predict therapeutic response
- Functional genomics to validate drug targets and mechanisms of action
- Clinical trial optimization platform to improve patient selection and treatment strategies
- Preclinical asset evaluation to de-risk drug development
- Target discovery and evaluation to identify novel therapeutic targets